Alphatec (ATEC) to Release Earnings on Thursday

Alphatec (NASDAQ:ATEC) is expected to issue its Q3 2025 results after the market closes on Thursday, October 30th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $182.7760 million for the quarter. Alphatec has set its FY 2025 guidance at EPS.Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, October 30, 2025 at 4:30 PM ET.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.08. The business had revenue of $185.54 million for the quarter, compared to the consensus estimate of $178.85 million. Alphatec’s revenue was up 27.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.29) EPS. On average, analysts expect Alphatec to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Alphatec Stock Performance

NASDAQ:ATEC opened at $16.58 on Tuesday. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. The firm’s fifty day simple moving average is $15.18 and its 200 day simple moving average is $13.07. The stock has a market cap of $2.45 billion, a P/E ratio of -14.67 and a beta of 1.05. Alphatec has a twelve month low of $5.18 and a twelve month high of $16.75.

Insider Transactions at Alphatec

In other news, Director Mortimer Berkowitz III sold 62,500 shares of the stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $15.97, for a total transaction of $998,125.00. Following the sale, the director owned 618,050 shares in the company, valued at $9,870,258.50. This represents a 9.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Patrick Miles sold 300,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $15.73, for a total value of $4,719,000.00. Following the completion of the transaction, the chief executive officer directly owned 5,564,078 shares in the company, valued at $87,522,946.94. This trade represents a 5.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 780,575 shares of company stock valued at $11,769,527. 22.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Alphatec

Several large investors have recently bought and sold shares of the business. Osterweis Capital Management Inc. purchased a new position in Alphatec in the 2nd quarter worth about $37,000. State of Wyoming bought a new stake in shares of Alphatec in the second quarter worth approximately $124,000. Tower Research Capital LLC TRC raised its holdings in shares of Alphatec by 536.4% during the second quarter. Tower Research Capital LLC TRC now owns 14,815 shares of the medical technology company’s stock valued at $164,000 after purchasing an additional 12,487 shares during the last quarter. Bayesian Capital Management LP bought a new position in Alphatec during the second quarter valued at approximately $173,000. Finally, Quantbot Technologies LP purchased a new stake in Alphatec in the second quarter worth approximately $242,000. 66.35% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $20.00 price target on shares of Alphatec in a research report on Friday, August 1st. Barclays reiterated an “overweight” rating and set a $22.00 target price (up previously from $21.00) on shares of Alphatec in a report on Monday, August 4th. JPMorgan Chase & Co. started coverage on Alphatec in a research note on Friday. They issued an “overweight” rating and a $19.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Alphatec in a research report on Tuesday, October 14th. Finally, Wall Street Zen upgraded Alphatec from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Alphatec presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.